Despite major scientific and technological advances, relatively few truly innovative drugs are approved today. The aim of CeBIL is to analyse the most important legal obstacles to pharmaceutical innovation and thereby contribute to translating innovative biomedical research into new effective, affordable, and easily accessible forms of treatment.
The goal of the programme is to propose new frameworks for developing and regulating medicines. This will entail the generation and use of empirical data to enable rational and well-informed policies to be developed in the field and to facilitate the transition from research to innovation.
The Foundation awarded DKK 35 million in 2018 to establish CeBIL, an international and interdisciplinary research programme that includes collaboration with experts based in Denmark and elsewhere from academia, public authorities, patient organisations, and industry.
A further DKK 50 million was granted in 2023 for the International Collaborative Biomedical Innovation & Law Programme (Inter-CeBIL), a continuation and expansion of CeBIL.
